Abstract

  Medulloblastoma (MB) constitutes the commonest malignant childhood brain cancer, and it is the leading cause of death in infants under 1 year. Treatment approaches, such as surgery, radiation, and chemotherapy, have significantly enhanced in patients’ clinical outcome with approximately more than 60% of 5-year survival. Nevertheless, the majority of cancer patients deal with long-term side effects. So, it is important to develop novel therapeutics with lower toxicity and increased efficacy. The present project was conducted to examine if the anti-allergy drugs can inhibit the cancer growth. More specifically, eight anti-allergy compounds, designed by the chemists at University of Central Lancashire (UCLAN), were evaluated for their anti-cancer activity against medulloblastoma. The effect of each testing drug was tested with the use of MTT assay after three days of incubation on medulloblastoma ONS76 cell line. From the extraction of the results of these anti-allergy compounds, it was found that only three of them (CL1-45-1, CL1-56-1, CL1-57-1) were more active, as they significantly inhibited the cancer growth. But, the CL1-42-1 compound displayed the greatest anti-cancer activity against the medulloblastoma ONS76 cells with IC50 = >10 μΜ (IC50 = 0 μΜ). This leads to the conclusion for further investigation of the anti-allergy compounds in order to consider them as potential anti-cancer agents.

Keywords: Anti-Allergy Drugs; Cancer; Anti-Cancer Agents, Drug-repurposing

References

1. Hanahan D and Weinberg R. “Hallmarks of Cancer: The Next Generation”. Cell 5 (2011): 646-674.
2. Sleire L., et al. “Drug repurposing in cancer”. Pharmacological Research 124 (2017): 74-91.
3. McGuire S. “World Cancer Report 2014. Geneva, Switzerland: World Health Organization, International Agency for Research on Cancer, WHO Press, 2015”. Advances in Nutrition2 (2016): 418-419.
4. Ostrom Q., et al. “CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2008-2012”. Neuro-Oncology4 (2015): iv1-iv62.
5. Ward E., et al. “Childhood and adolescent cancer statistics, 2014”. CA: A Cancer Journal for Clinicians2 (2014): 83-103.
6. Ferlay J., et al. “Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012”. - PubMed - NCBI (2013).
7. Sondka Z., et al. “The COSMIC Cancer Gene Census: describing genetic dysfunction across all human cancers”. Nature Reviews Cancer11 (2018): 696-705.
8. Stratton M., et al. “The cancer genome”. Nature7239 (2009): 719-724.
9. Silva P., et al. “Establishment of a novel human medulloblastoma cell line characterized by highly aggressive stem-like cells”. Cytotechnology 4 (2015): 1545-1560.
10. Yi J and Wu J. “Epigenetic regulation in medulloblastoma”. Molecular And Cellular Neuroscience 87 (2018): 65-76.
11. Northcott P., et al. “Molecular subgroups of medulloblastoma”. Expert Review of Neurotherapeutics7 (2012): 871-884.
12. Northcott PA., et al. “Enhancer hijacking activates GFI1 family oncogenes in medulloblastoma”. Nature 511 (2014): 428-434.
13. Presutto E., et al. “Posterior fossa medulloblastoma in an atypical extra-axial location: A case report”. Radiology Case Reports2 (2018): 365-370.
14. Kumar V., et al. “Challenges and Recent Advances in Medulloblastoma Therapy”. Trends in Pharmacological Sciences12 (2017): 1061-1084.
15. Amin A., et al. “Evasion of anti-growth signaling: A key step in tumorigenesis and potential target for treatment and prophylaxis by natural compounds”. Seminars in Cancer Biology 35 (2015): S55-S77.
16. Taylor M., et al. “Molecular subgroups of medulloblastoma: the current consensus”. Acta Neuropathologica 4 (2011): 465-472.
17. Taylor MD., et al. “Molecular subgroups of medulloblastoma: the current consensus”. Acta Neuropathologica 123 (2012): 465-472.
18. Taylor R., et al. “Results of a Randomized Study of Preradiation Chemotherapy Versus Radiotherapy Alone for Nonmetastatic Medulloblastoma: The International Society of Paediatric Oncology/United Kingdom Children’s Cancer Study Group PNET-3 Study”. Journal of Clinical Oncology8 (2003): 1581-1591.
19. Jones D., et al. “Dissecting the genomic complexity underlying medulloblastoma”. Nature7409 (2012):100-105.
20. Parsons D., et al. “The Genetic Landscape of the Childhood Cancer Medulloblastoma”. Science 6016 (2010): 435-439.
21. Pugh T., et al. “Medulloblastoma exome sequencing uncovers subtype-specific somatic mutations”. Nature 7409 (2012): 106-110.
22. Robinson G., et al. “Novel mutations target distinct subgroups of medulloblastoma”. Nature 7409 (2012): 43-48.
23. Kool M., et al. “Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas”. Acta Neuropathologica4 (2012): 473-484.
24. Cavalli A., et al. “Dynamic Docking: A Paradigm Shift in Computational Drug Discovery”. Molecules 11 (2017): 2029.
25. Gibson P., et al. “Subtypes of medulloblastoma have distinct developmental origins”. Nature 468 (2010): 1095-1099.
26. Zhukova I., et al. “Behavioral impairment in Parkinson's Disease in the Siberian region”. Journal of the Neurological Sciences 333 (2013): e110-e111.
27. Kool M., et al. “Genome sequencing of SHH medulloblastoma predicts genotype-related response to smoothened inhibition”. Cancer Cell 25 (2014): 393-405.
28. Boolell M., et al. “Sildenafil, a novel effective oral therapy for male erectile dysfunction”. British Journal of Urology2 (1996): 257-261.
29. Li YY and Jones SJ. “Drug repositioning for personalized medicine”. Genome Medicine 4 (2012): 27.
30. Shih T., et al. “The Effects of Anodization Treatment on the Microstructure and Fatigue Behavior of 7075-T73 Aluminum Alloy”. Materials Transactions8 (2014): 1280-1285.
31. Ramaswamy V., et al. “Risk stratification of childhood medulloblastoma in the molecular era: the currentconsensus”. Acta Neuropathologica (2016).
32. Remke M., et al. “FSTL5 is a marker of poor prognosis in non-WNT/non-SHH medulloblastoma”. Journal of Clinical Oncology 29 (2013): 3852-3861.
33. Hatten M and Roussel M. “Development and cancer of the cerebellum”. Trends in Neurosciences3 (2011): 134-142.
34. Roussel M and Robinson G. “Role of MYC in Medulloblastoma”. Cold Spring Harbor Perspectives in Medicine11 (2013): a014308-a014308.
35. Wenger SL., et al. “Comparison of established cell lines at different passages by karyotype and comparative genomic hybridization”. Bioscience Reports 24 (2004): 631-639.
36. Langdon J., et al. “Combined genome-wide allelotyping and copy number analysis identify frequent genetic losses without copy number reduction in medulloblastoma”. Genes, Chromosomes and Cancer1 (2006): 47-60.
37. Xu J., et al. “Pediatric brain tumor cell lines”. Journal of Cellular Biochemistry 116 (2015a): 218-224.
38. Ghassemifar S and Mendrysa SM. “MDM2 antagonism by nutlin-3 induces death in human medulloblastoma cells”. Neuroscience Letters 513 (2012): 106-110.
39. Kunkele A., et al. “Pharmacological activation of the p53 pathway by nutlin-3 exerts anti-tumoral effects in medulloblastomas”. Neuro-Oncology 14 (2012): 859-869.
40. Othman RT., et al. “Overcoming multiple drug resistance mechanisms in medulloblastoma”. Acta Neuropathologica Communications 2 (2014): 57.
41. Lacroix J., et al. “Parvovirus H-1 (H-1PV) exerts oncolytic effects in cell culture models of human brain tumor-initiating cells”. Klinische Pädiatrie06 (2014).
42. Hill J., et al. “Reducing obesity will require involvement of all sectors of society”. Obesity2 (2015): 255-255.
43. Snuderl, M., et al. “Targeting placental growth factor/neuropilin 1 pathway inhibits growth andspread of medulloblastoma”. Cell 152 (2013): 1065-1076.
44. Sengupta S., et al. “5-GABAA receptors negatively regulate MYC-amplified medulloblastoma growth”. Acta Neuropathologica 127 (2014): 593-603.
45. Weeraratne SD., et al. “Pleiotropic effects of miR-183 ∼ 96 ∼ 182converge to regulate cell survival, proliferation and migration in medulloblastoma”. Acta Neuropathologica 123 (2012): 539-552.
46. Robertson PL., et al. “Incidence and severity of postoperative cerebellar mutism syndrome in children with medulloblastoma: a prospective study by the Children’s Oncology Group”. Journal of Neurosurgery 105 (2006): 444-451.
47. Mulhern RK., et al. “Neurocognitive consequences of risk-adapted therapy for childhood medulloblastoma”. Journal of Clinical Oncology 23 (2005): 5511-5519.
48. Boman K., et al. “Disability, body image and sports/physical activity in adult survivors of childhood CNS tumors: population-based outcomes from a cohort study”. Journal of Neuro-Oncology1 (2013): 99-106.
49. Packer RJ., et al. “Treatment of children with medulloblastomas with reduced-dose craniospinal radiation therapy and adjuvant chemotherapy: A Children’s Cancer Group Study”. Journal of Clinical Oncology 17 (1999): 2127-2136.
50. Ashburn T and Thor K. “Drug repositioning: identifying and developing new uses for existing drugs”. Nature Reviews Drug Discovery8 (2004): 673-683.
51. Tobinick EL. “The value of drug repositioning in the current pharmaceutical market”. Drug News Perspect 22 (2009): 119-125.
52. Deotarse PP., et al. “Drug repositioning: a review”. International Journal of Pharmaceutical Sciences Review and Research 4 (2015): 51-58.
53. Chong C and Sullivan D. “New uses for old drugs”. Nature7154 (2007): 645-646.
54. Smith RB. “Repositioned drugs: integrating intellectual property and regulatory strategies”. Drug Discovery Today: Therapeutic Strategies 8 (2011): 131.
55. Padhy BM and Gupta YK. “Drug repositioning: re-investigating existing drugs for new therapeutic indications”. Journal of Postgraduate Medicine 57 (2011): 153-160.
56. McBride W. “Thalidomide embryopathy”. Teratology1 (1977): 79-82.
57. D'Amato R., et al. “Thalidomide is an inhibitor of angiogenesis”. Proceedings of the National Academy of Sciences9 (1994): 4082-4085.
58. Singhal S., et al. “Antitumor activity of thalidomide in refractory multiple myeloma”. The New England Journal of Medicine 341 (1999): 1565-1571.
59. Ning YM., et al. “Phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer”. Journal of Clinical Oncology 28 (2010): 2070-2076.
60. Huang R., et al. “The NCGC Pharmaceutical Collection: A Comprehensive Resource of Clinically Approved Drugs Enabling Repurposing and Chemical Genomics”. Science Translational Medicine80 (2011): 80ps16-80ps16.
61. Pantziarka P., et al. “The repurposing drugs in oncology (ReDO) project”. Ecancer 8 (2014): 442.
62. Vinogradov S and Wei X. “Cancer stem cells and drug resistance: the potential of nanomedicine”. Nanomedicine4 (2012): 597-615.

Citation

Citation: Moschou Georgia and Topham H Caroline. “Drug Re-Purposing - Can Anti-Allergy Drugs also be Used to Treat Cancer ?". Acta Scientific Microbiology 3.7 (2020): 31-45.

Copyright

Copyright: © 2020 Moschou Georgia and Topham H Caroline. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.